Inovio Pharmaceuticals, Inc.
Inovio Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $65,300.00, down 70.0% from fiscal 2024. In the quarter to June 2026, revenue fell 83.2%, EPS grew 88.5% and free cash flow grew 13.4%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
Follow INO
Inovio Pharmaceuticals, Inc. (INO) EV/Sales
As of 16 October 2026, Inovio Pharmaceuticals, Inc. (INO) trades at a EV/Sales of 157×. Over the past ten years it has ranged from −66.6× (November 2023) to 1,439× (June 2020); the current reading is higher than 76% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 103× | — |
| FY2024 | −39.2× | — |
| FY2023 | 24.4× | 98.52% |
| FY2022 | 12.3× | (96.67%) |
| FY2021 | 369× | 179.59% |
| FY2020 | 132× | 73.53% |
| FY2019 | 76.1× | 703.79% |
| FY2018 | 9.5× | 56.77% |
| FY2017 | 6.0× | (48.21%) |
| FY2016 | 11.7× | 60.40% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Mar 2025 | 29.0× | — |
| Dec 2024 | −39.2× | — |
| Jun 2024 | 172× | 602.34% |
| Dec 2023 | 24.4× | — |
| 35 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| LENZ LENZ Therapeutics, Inc. compare | −5.4× |
| SEER Seer, Inc. compare | −2.9× |
| TNXP Tonix Pharmaceuticals Holding Corp. compare | −2.3× |
| FHTX Foghorn Therapeutics Inc. compare | −0.5× |
| CYTT Cyteir Therapeutics, Inc. compare | n/m |
| VTVT vTv Therapeutics Inc. compare | 6.5× |
| GNLX Genelux Corporation compare | 8.8× |
| VANI Vivani Medical, Inc. compare | 23.6× |
| INO Inovio Pharmaceuticals, Inc. | 157× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)